RT Journal Article SR Electronic T1 Marginal Value of Quarantine JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2020.11.24.20238204 DO 10.1101/2020.11.24.20238204 A1 James Petrie A1 Joanna Masel YR 2020 UL http://medrxiv.org/content/early/2020/11/28/2020.11.24.20238204.abstract AB Different combinations of targeted quarantine and broad scale social distancing are equally capable of stemming the transmission of a virus like SARS-CoV-2. Finding the optimal balance between these policies can be operationalized by minimizing the total amount of social isolation needed to achieve a target reproductive number. This results in a risk threshold for triggering quarantine that depends strongly on disease prevalence in a population, suggesting that very different disease control policies should be used at different times or places. Very aggressive quarantine is warranted given low disease prevalence, while populations with a higher base rate of infection should rely more on broad social distancing. Total cost to a society can be greatly reduced given modestly more information about individual risk of infectiousness.Competing Interest StatementJoanna Masel consults for WeHealth, distributor of the Covid Watch app to Arizona. James Petrie is likely to soon sign a contract giving him an equity interest in WeHealth.Funding StatementJames Petrie received funding from the Ontario Graduate Scholarship and the University of Waterloo.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:NAAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNA